Abstract:Introduction & Objective: Ecnoglutide (XW003) is a cAMP-biased GLP-1 analog being developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The objective of this analysis was to compare the preclinical and clinical efficacy of ecnoglutide to unbiased GLP-1 peptides. Methods: Ecnoglutide was assessed for cAMP production and β-arrestin recruitment in GLP-1R reporter cell lines. Glucose control was tested in db/db mice administered a single subcutaneous dose of GLP-1 analogs, with blood glucose recorded for 144 h. Body weight and insulin response were evaluated in db/db mice dosed with once daily injections of GLP-1 analogs for 42 days. A 20 week Phase 2 study was conducted in 145 patients with T2DM (ecnoglutide 0.4, 0.8, or 1.2 mg). Comparator clinical results were obtained from published reports. Results: In vitro, cAMP induction was similar for ecnoglutide and semaglutide. EC50 values for β-arrestin recruitment were also similar, however, maximum recruitment and receptor internalization were lower for ecnoglutide. In mice, a single dose of ecnoglutide led to more sustainable decreases in blood glucose compared to semaglutide, extending glucose suppression by up to 48 h. In mice, ecnoglutide also significantly improved weight control and induced higher levels of insulin versus semaglutide. The increased preclinical potency of ecnoglutide translated into clinical efficacy. T2DM patients administered up to 1.2 mg ecnoglutide for 20 weeks had a -2.39% reduction in HbA1c. This compared to -1.14% reported for liraglutide (1.8 mg at 52 weeks), -1.55% to -1.86% for semaglutide (1.0 mg at 30-40 weeks), and -1.46% for dulaglutide (1.5 mg at 26 weeks). Furthermore, 1.2 mg ecnoglutide showed comparable HbA1c reductions to the biased dual GIP/GLP-1 receptor agonist, tirzepatide (15 mg), which reduced HbA1c by -2.30% at 40 weeks. Conclusion: Bias for the cAMP pathway results in sustained signaling that correlates with increased clinical efficacy compared to unbiased GLP-1 analogs. Disclosure G. Wanjun: Employee; Sciwind Biosciences. H. Zou: Employee; Sciwind Biosciences. Z. Zhu: None. Y. Li: Employee; Sciwind Biosciences. J. Ning: None. Q. Zheng: Employee; Sciwind Biosciences. Y. Li: Employee; Sciwind Biosciences. R. Zhu: Employee; Sciwind Biosciences. C.L. Jones: Employee; Sciwind Biosciences. M. Fenaux: None. S. Xu: None. M.K. Junaidi: None. Funding Sciwind Biosciences

The GLP-1R as a model for understanding and exploiting biased agonism in next generation medicines.

Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors

Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors

Structure and Molecular Mechanism of Signaling for the Glucagon-like Peptide-1 Receptor Bound to Gs Protein and Exendin-P5 Biased Agonist

Understanding the mechanism of bias signaling of the insulin-like growth factor 1 receptor: Effects of LL37 and HASF

Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Does GIPR blockade as well as agonism have a role to play in management of obesity and diabetes?

Targeting GLP-1 receptor trafficking to improve agonist efficacy

Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects

Control of insulin secretion by GLP-1

Binding sites and design strategies for small molecule GLP-1R agonists

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects

Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: Alternative approaches for treatment of Type 2 diabetes

Class B1 GPCRs: Insights into Multi-Receptor Pharmacology for the Treatment of Metabolic Disease

Mechanisms of signalling and biased agonism in G protein-coupled receptors

Bias translation: The final frontier?

793-P: Biased GLP-1 Analog Ecnoglutide (XW003) Has Improved Efficacy Relative to Unbiased Peptides

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms